Clinical trials: Pregnant Women
Overactive Bladder
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from…
- Trial name
- NCT01458197
- Testing
- Tarafenacin 0.2 mg, Tarafenacin 0.4 mg
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Overactive Bladder, Nocturia
NOGO for an Overactive Bladder
This is a double-blind, randomized and placebo-controlled study to evaluate the safety and effectiveness of NoGo, a standardized extract from Angelica archangelica, on overactive bladder
- Trial name
- NOGO-OAB (NCT04357223)
- Testing
- extract from Angelica archangelica leaf
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- SagaNatura
Kidney Diseases, Renal Insufficiency
Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.
- Trial name
- NCT00358046
- Testing
- ILY101
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ilypsa
Liver Cirrhosis
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
- Trial name
- NCT06715670
- Testing
- Zibotentan
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Failure, End Stage Renal Disease
Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis Patients in Turkey
Development, feasibility testing and validation of a Survey Set to Measure Patient-Reported Outcomes among Hemodialysis Patients in Turkey: Creating and testing an electronic patient questionnaire that is suitable to measure…
- Trial name
- DOPRO (NCT05441020)
- Testing
- Administration of patient questionnaire
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 173 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.
- Conditions
- Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
- Trial name
- NCT06265220
- Testing
- AB-101, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Overactive Bladder, Urge Incontinence
AURA-2: Augmenting Urinary Reflex Activity
AMBER AURA-2 study (Augmenting Urinary Reflex Activity 2) is a short-duration (6 month) safety and electrophysiological study using an implanted Amber UI system and two electrode leads to provide closed-loop pudendal nerve…
- Trial name
- AURA-2 (NCT05241379)
- Testing
- Amber UI System
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Amber Therapeutics Ltd
Ovarian Cancer
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer.
- Trial name
- NCT03639246
- Testing
- AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD)
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Aravive, Inc.
GYN Disorders
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications Generate real-world evidence in the use of the da Vinci Surgical Systems for gynecological indications within the German…
- Trial name
- GENERATE (NCT05867927)
- Testing
- Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
- Where
- 15 sites in Germany
- Volunteers
- 1,250 people
- Sponsor
- Intuitive Surgical
Renal Failure, Renal Artery Stenosis
Renal Blood Flow Measurement With Positron Emission Tomography (PET)
Two investigational chemical tracers, 62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS) and 15O-water, will be used in this study to look at how blood moves through the kidneys.
- Trial name
- NCT00714142
- Testing
- 62Cu-ethylglyoxal bis(thiosemicarbazone), 15O-water, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jeffrey L. Lacy
Anemia, Renal Insufficiency, Chronic
15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood.
- Trial name
- DIALOGUE 1 (NCT02021370)
- Testing
- BAY85-3934
- Where
- 56 sites in Australia, Bulgaria and 12 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Cystitis, Interstitial
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
- Trial name
- NCT00380783
- Testing
- AGN 203818
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Allergan
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT07159841
- Testing
- Atumelnant
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 153 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Gestational Diabetes
Mobile Health App to Reduce Diabetes in Latina Women
The proposed project sought to develop a culturally- and individually-tailored, plain-language Spanish/English mobile phone intervention for Latinas with prior gestational diabetes (GDM).
- Trial name
- NCT04149054
- Testing
- Mobile health app called "Hola Bebe"
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Environment and Health Group, Inc.
Postpartum Depression
Pivotal Test: WB001
The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to : 1.
- Trial name
- NCT04576754
- Testing
- WB001, Educational
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Woebot Health
Kidney Stone, Renal Stone
Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)
The purpose of the study is to compare the effects, good and/or bad, of a treatment for removing kidney stones called the SURE procedure for stone evacuation to the standard treatment using a basket for stone removal.
- Conditions
- Kidney Stone, Renal Stone, Urolithiasis
- Trial name
- NCT04519294
- Testing
- SURE, Standard Ureteroscopy (Basketing)
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Calyxo, Inc.
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
Ovarian Cancer, Fallopian Tube Cancer
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- VITALIA (NCT03905902)
- Testing
- DCVAC/OvCa
- Sponsor
- SOTIO a.s.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.